CAFs and TGF-β Signaling Activation by Mast Cells Contribute to Resistance to Gemcitabine/Nabpaclitaxel in Pancreatic Cancer

CXCL9, CXCL10, CXCL11/CXCR3 axis for immune activation – A target for novel cancer therapy

(2018) Ryuma Tokunaga et al.   CANCER TREATMENT REVIEWS

Signaling Crosstalk of TGF-β/ALK5 and PAR2/PAR1: A Complex Regulatory Network Controlling Fibrosis and Cancer

(2018) Hendrik Ungefroren et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

Suppression of IL-6 Gene by shRNA Augments Gemcitabine Chemosensitization in Pancreatic Adenocarcinoma Cells

(2018) Hai-Bo Xing et al.   Biomed Research International

Galunisertib plus gemcitabine vs. gemcitabine for first-line treatment of patients with unresectable pancreatic cancer

(2018) Davide Melisi et al.   BRITISH JOURNAL OF CANCER

Proteinase-Activated Receptor 2 May Drive Cancer Progression by Facilitating TGF-β Signaling

(2017) Hendrik Ungefroren et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

Targeting human liver cancer cells with lactobionic acid-G(4)-PAMAM-FITC sorafenib loaded dendrimers

(2017) Rosa Maria Iacobazzi et al.   INTERNATIONAL JOURNAL OF PHARMACEUTICS

TGFβ engages MEK/ERK to differentially regulate benign and malignant pancreas cell function

(2017) D R Principe et al.   ONCOGENE

Mast cells decrease efficacy of anti-angiogenic therapy by secreting matrix-degrading granzyme B

(2017) M. Wroblewski et al.   Nature Communications

Grape seed extracts modify the outcome of oxaliplatin in colon cancer cells by interfering with cellular mechanisms of drug cytotoxicity

(2017) Letizia Porcelli et al.   Oncotarget

A Novel MIF Signaling Pathway Drives the Malignant Character of Pancreatic Cancer by Targeting NR3C2

(2016) Shouhui Yang et al.   CANCER RESEARCH

Hepatic stellate cells induce hepatocellular carcinoma cell resistance to sorafenib through the laminin-332/α3 integrin axis recovery of focal adhesion kinase ubiquitination

(2016) Amalia Azzariti et al.   HEPATOLOGY

Genomic analyses identify molecular subtypes of pancreatic cancer

(2016) Peter Bailey et al.   NATURE

Cytokines as Biomarkers of Pancreatic Ductal Adenocarcinoma: A Systematic Review

(2016) Yandiswa Yolanda Yako et al.   PLoS One

Key players in pancreatic cancer-stroma interaction: Cancer-associated fibroblasts, endothelial and inflammatory cells

(2016) Michael Friberg Bruun Nielsen et al.   WORLD JOURNAL OF GASTROENTEROLOGY

Proteinase-activated receptor 2 promotes TGF-β-dependent cell motility in pancreatic cancer cells by sustaining expression of the TGF-β type I receptor ALK5

(2016) Franziska Zeeh et al.   Oncotarget

nab-Paclitaxel Plus Gemcitabine for Metastatic Pancreatic Cancer: Long-Term Survival From a Phase III Trial

(2015) D. Goldstein et al.   JNCI-Journal of the National Cancer Institute

Mast cells as targets for immunotherapy of solid tumors

(2015) Sharon A. Oldford et al.   MOLECULAR IMMUNOLOGY

nab-Paclitaxel Plus Gemcitabine for Metastatic Pancreatic Cancer: Long-Term Survival From a Phase III Trial

(2015) D. Goldstein et al.   JNCI-Journal of the National Cancer Institute

Stromal disrupting effects of nab-paclitaxel in pancreatic cancer

(2013) R Alvarez et al.   BRITISH JOURNAL OF CANCER

Serum levels of IL-6 and IL-1β can predict the efficacy of gemcitabine in patients with advanced pancreatic cancer

(2013) S Mitsunaga et al.   BRITISH JOURNAL OF CANCER

TGF-β: An emerging player in drug resistance

(2013) Diede Brunen et al.   CELL CYCLE

TGF-β inhibition enhances chemotherapy action against triple-negative breast cancer

(2013) Neil E. Bhola et al.   JOURNAL OF CLINICAL INVESTIGATION

Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine

(2013) Daniel D. Von Hoff et al.   NEW ENGLAND JOURNAL OF MEDICINE

Intratumoral mast cells promote the growth of pancreatic cancer

(2013) Ying Ma et al.   OncoImmunology

Systemic sclerosis endothelial cells recruit and activate dermal fibroblasts by induction of a connective tissue growth factor (CCN2)/transforming growth factor β-dependent mesenchymal-to-mesenchymal transition

(2012) Simona Serratì et al.   ARTHRITIS AND RHEUMATISM

Enzymatic Targeting of the Stroma Ablates Physical Barriers to Treatment of Pancreatic Ductal Adenocarcinoma

(2012) Paolo P. Provenzano et al.   CANCER CELL

Molecular Pathology of Pancreatic Cancer: From Bench-to-Bedside Translation

(2012) Vincenzo Corbo et al.   CURRENT DRUG TARGETS

Macrophage migration inhibitory factor induces epithelial to mesenchymal transition, enhances tumor aggressiveness and predicts clinical outcome in resected pancreatic ductal adenocarcinoma

(2012) Naotake Funamizu et al.   INTERNATIONAL JOURNAL OF CANCER

FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer

(2011) Thierry Conroy et al.   NEW ENGLAND JOURNAL OF MEDICINE

Crosstalk between Mast Cells and Pancreatic Cancer Cells Contributes to Pancreatic Tumor Progression

(2010) M. J. Strouch et al.   CLINICAL CANCER RESEARCH

Inhibition of Hedgehog Signaling Enhances Delivery of Chemotherapy in a Mouse Model of Pancreatic Cancer

(2009) K. P. Olive et al.   SCIENCE

Cancer-Associated Stromal Fibroblasts Promote Pancreatic Tumor Progression

(2008) R. F. Hwang et al.   CANCER RESEARCH

TGFβ in Cancer

(2008) Joan Massagué   CELL

LY2109761, a novel transforming growth factor   receptor type I and type II dual inhibitor, as a therapeutic approach to suppressing pancreatic cancer metastasis

(2008) D. Melisi et al.   MOLECULAR CANCER THERAPEUTICS

Core Signaling Pathways in Human Pancreatic Cancers Revealed by Global Genomic Analyses

(2008) S. Jones et al.   SCIENCE